Authors: Michele Tanturli, Serena Giuntoli, Valentina Barbetti, Elisabetta Rovida, Persio Dello Sbarba
DOI: 10.1371/journal.pone.0017008
Abstract Summary
Severe hypoxia selects for chronic myeloid leukemia stem cells that resist both targeted therapy and proteasome inhibition. Researchers found that hypoxia-adapted CML stem cells from patients showed complete resistance to Bortezomib, mimicking the oxygen-poor bone marrow niches where these cells hide in vivo and sustain minimal residual disease.
Why Brain? ๐ง
Hypoxia in bone marrow selects for chronic myeloid leukemia stem cells resistant to both targeted therapy and proteasome inhibitors, explaining treatment failure and disease relapse in protected niches.
License: CC BY.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
